This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessReview
Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview
by
Isabella Spinello
Isabella Spinello ,
Catherine Labbaye
Catherine Labbaye and
Ernestina Saulle
Ernestina Saulle *
Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(17), 9178; https://doi.org/10.3390/ijms25179178 (registering DOI)
Submission received: 29 July 2024
/
Revised: 21 August 2024
/
Accepted: 22 August 2024
/
Published: 23 August 2024
Abstract
Hematological malignancies refer to a heterogeneous group of neoplastic conditions of lymphoid and hematopoietic tissues classified in leukemias, Hodgkin and non-Hodgkin lymphomas and multiple myeloma, according to their presumed cell of origin, genetic abnormalities, and clinical features. Metabolic adaptation and immune escape, which influence various cellular functions, including the proliferation and survival of hematological malignant tumor cells, are major aspects of these malignancies that lead to therapeutic drug resistance. Targeting specific metabolic pathways is emerging as a novel therapeutic strategy in hematopoietic neoplasms, particularly in acute myeloid leukemia and multiple myeloma. In this context, CD147, also known as extracellular matrix metalloproteinase inducer (EMMPRIN) or Basigin, is one target candidate involved in reprograming metabolism in different cancer cells, including hematological malignant tumor cells. CD147 overexpression significantly contributes to the metabolic transformation of these cancer cells, by mediating signaling pathway, growth, metastasis and metabolic reprogramming, through its interaction, direct or not, with various membrane proteins related to metabolic regulation, including monocarboxylate transporters, integrins, P-glycoprotein, and glucose transporter 1. This review explores the metabolic functions of CD147 and its impact on the tumor microenvironment, influencing the progression and neoplastic transformation of leukemias, myeloma, and lymphomas. Furthermore, we highlight new opportunities for the development of targeted therapies against CD147, potentially improving the treatment of hematologic malignancies.
Share and Cite
MDPI and ACS Style
Spinello, I.; Labbaye, C.; Saulle, E.
Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview. Int. J. Mol. Sci. 2024, 25, 9178.
https://doi.org/10.3390/ijms25179178
AMA Style
Spinello I, Labbaye C, Saulle E.
Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview. International Journal of Molecular Sciences. 2024; 25(17):9178.
https://doi.org/10.3390/ijms25179178
Chicago/Turabian Style
Spinello, Isabella, Catherine Labbaye, and Ernestina Saulle.
2024. "Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview" International Journal of Molecular Sciences 25, no. 17: 9178.
https://doi.org/10.3390/ijms25179178
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.